OTC Markets OTCPK - Delayed Quote USD

Innovent Biologics, Inc. (IVBXF)

Compare

4.5294

0.0000

(0.00%)

At close: January 10 at 3:00:00 PM EST

Currency in CNY All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

6,206,070.0000

4,556,380.0000

4,269,729.0000

3,843,819.0000

Cost of Revenue

1,136,266.0000

930,990.0000

505,337.0000

387,761.0000

Gross Profit

5,069,804.0000

3,625,390.0000

3,764,392.0000

3,456,058.0000

Operating Expense

5,979,014.0000

6,207,275.0000

5,703,539.0000

3,498,501.0000

Operating Income

-909,210.0000

-2,581,885.0000

-1,939,147.0000

-42,443.0000

Net Non Operating Interest Income Expense

354,213.0000

87,839.0000

89,291.0000

47,752.0000

Pretax Income

-1,144,411.0000

-2,170,469.0000

-2,641,717.0000

-858,713.0000

Tax Provision

-116,498.0000

8,801.0000

87,038.0000

139,708.0000

Net Income Common Stockholders

-1,027,913.0000

-2,179,270.0000

-2,728,755.0000

-998,421.0000

Diluted NI Available to Com Stockholders

-1,027,913.0000

-2,179,270.0000

-2,728,755.0000

-998,421.0000

Basic EPS

-0.66

-1.46

-1.88

-0.74

Diluted EPS

-0.66

-1.46

-1.88

-0.74

Basic Average Shares

1,559,637.0040

1,490,123.1920

1,455,605.7510

1,357,011.7570

Diluted Average Shares

1,559,637.0040

1,490,123.1920

1,455,605.7510

1,357,011.7570

Total Expenses

7,115,280.0000

7,138,265.0000

6,208,876.0000

3,886,262.0000

Net Income from Continuing & Discontinued Operation

-1,027,913.0000

-2,179,270.0000

-2,728,755.0000

-998,421.0000

Normalized Income

-1,054,728.8403

-2,183,141.5000

-2,821,986.0000

-1,020,753.0000

Interest Income

452,837.0000

189,537.0000

151,755.0000

116,102.0000

Interest Expense

98,624.0000

101,698.0000

62,464.0000

68,350.0000

Net Interest Income

354,213.0000

87,839.0000

89,291.0000

47,752.0000

EBIT

-1,045,787.0000

-2,068,771.0000

-2,579,253.0000

-790,363.0000

EBITDA

-660,684.0000

-1,749,349.0000

-2,374,506.0000

-704,736.0000

Reconciled Cost of Revenue

1,136,266.0000

930,990.0000

505,337.0000

387,761.0000

Reconciled Depreciation

385,103.0000

319,422.0000

204,747.0000

85,627.0000

Net Income from Continuing Operation Net Minority Interest

-1,027,913.0000

-2,179,270.0000

-2,728,755.0000

-998,421.0000

Total Unusual Items Excluding Goodwill

29,855.0000

5,162.0000

124,308.0000

29,776.0000

Total Unusual Items

29,855.0000

5,162.0000

124,308.0000

29,776.0000

Normalized EBITDA

-690,539.0000

-1,754,511.0000

-2,498,814.0000

-734,512.0000

Tax Rate for Calcs

0.0001

0.0003

Tax Effect of Unusual Items

3,039.1597

1,290.5000

31,077.0000

7,444.0000

12/31/2020 - 9/4/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

SHJBF Shanghai Junshi Biosciences Co., Ltd.

1.9700

+58.87%

BRAXF Braxia Scientific Corp.

0.0020

+33.33%

DMYD-B.ST Diamyd Medical AB (publ)

17.14

-5.20%

AVBP ArriVent BioPharma, Inc.

24.88

-7.37%

RLYB Rallybio Corporation

0.9400

-5.63%

LVTX LAVA Therapeutics N.V.

0.9758

-5.26%

LXEO Lexeo Therapeutics, Inc.

6.39

-6.30%

VIGL Vigil Neuroscience, Inc.

1.7900

-2.72%

ADVM Adverum Biotechnologies, Inc.

4.2700

-5.53%

TELO Telomir Pharmaceuticals, Inc.

4.1100

-4.42%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Innovent Biologics, Inc. (IVBXF)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers